Discovery of VEGFR inhibitors through virtual screening and energy assessment
- 19 February 2023
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 37 (5) , e23321
Abstract
Vascular endothelial growth factor receptor‐2 (VEGFR‐2) is crucial in promoting tumor angiogenesis and cancer metastasis. Thus, inhibition of VEGFR‐2 has appeared as a good tactic for cancer treatment. To find out novel VEGFR‐2 inhibitors, first, the PDB structure of VEGFR‐2, 6GQO, was selected based on atomic nonlocal environment assessment (ANOLEA) and PROCHECK assessment. 6GQO was then further used for structure‐based virtual screening (SBVS) of different molecular databases, including US‐FDA approved drugs, US‐FDA withdrawn drugs, may bridge, MDPI, and Specs databases using Glide. Based on SBVS, receptor fit, drug‐like filters, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis of 427877 compounds, the best 22 hits were selected. From the 22 hits, hit 5 complex with 6GQO was put through molecular mechanics/generalized born surface area (MM/GBSA) study and hERG binding. The MM/GBSA study revealed that hit 5 possesses lesser binding free energy with more inferior stability in the receptor pocket than the reference compound. The VEGFR‐2 inhibition assay of hit 5 disclosed an IC50 of 165.23 nM against VEGFR‐2, which can be possibly enhanced through structural modifications.Keywords
This publication has 20 references indexed in Scilit:
- Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry PerspectiveMedicine in Drug Discovery, 2019
- Phenyl and Diaryl Ureas with Thiazolo[5,4‐d]pyrimidine Scaffold as Angiogenesis Inhibitors: Design, Synthesis and Biological EvaluationChemistry & Biodiversity, 2019
- Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agentsBioorganic Chemistry, 2018
- Structure and function of vascular endothelial growth factor and its receptor systemBMB Reports, 2018
- VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)Expert Opinion on Therapeutic Patents, 2017
- A Comprehensive Docking and MM/GBSA Rescoring Study of Ligand Recognition upon Binding AntithrombinCurrent Topics in Medicinal Chemistry, 2017
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesScientific Reports, 2017
- A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting AngiogenesisJournal of Medicinal Chemistry, 2015
- pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based SignaturesJournal of Medicinal Chemistry, 2015
- Structure Assessment Analysis of Core Domain of Seven Protein Data Bank Entries of HIV-1 Protease Using Different in-silico TechniquesCurrent Enzyme Inhibition, 2015